Chennai, Jan 14 : Pharma major Glenmark Pharmaceuticals Limited on Friday said its fully owned Swiss subsidiary Glenmark Specialty S.A.
has received the US Food and Drug Administrations (FDA) approval for nasal spray fixed dose prescription drug for seasonal allergic rhinitis Ryaltris.According to Glenmark, the drug is for rhinitis in adults and paediatric patients 12 years of age and older in the US."The FDAs approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to bring innovative treatment options in our key therapeutic areas." said Chief Commercial Officer Robert Crockart.
Ryaltris will be marketed and distributed in America by Hikma Specialty U.S.A., Inc., as part of its exclusive licensing agreement with Glenmark Specialty S.A.Glenmark has entered into commercial agreements with several partners around the world, including Menarini for the commercialisation of Ryaltris in select EU markets, and with Bausch Health in Canada (where it is under review by Health Canada), the company said.vj/ksk/ #Glenmark #approval #nasal #spray #Chennai #Tamil #Kollywood #Jan #Chennai #America #Review.
Latest News
Download App
Channels
Home English News TeluguStop Exclusive Stories Flash/Breaking News Trending News Political Movie Health Tips Crime News Movie Reviews NRI News Viral Videos Bhakthi/Devotional Press Releases Viral Stories Quotes Photo Talks Baby Boy NamesBaby Girl Names Celebrity ProfilesFollow Us!
Contact Us!
TeluguStop.com Media, Siya Residency, Sri Sri Circle, Khammam, Telangana- 507002info@telugustop.com Ph No : 999-279-9973
About Us!
About Us Jobs Advertising DMCA / Removal Terms of Use Privacy Policy